DDInter76 DDInter927
Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxicity and possibly death, amiodarone use should be reserved for its approved indications, according to prescribing information.[L3561,L11265,L11286]
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Amiodarone {u} (Compound) resembles {v} (Compound) Dronedarone
Amiodarone {u} (Compound) resembles {v} (Compound) Lucanthone
Amiodarone {u} (Compound) binds {v} (Gene) CACNA2D2
Amiodarone {u} (Compound) upregulates {v} (Gene) HMGCS1
Amiodarone {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C9 Inhibitors
Amiodarone {u} (Compound) downregulates {v} (Gene) PRPF4
Amiodarone {u} (Compound) causes {v} (Side Effect) Dermatitis exfoliative
Amiodarone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Amiodarone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liothyronine
Amiodarone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nintedanib
Amiodarone (Compound) resembles Dronedarone (Compound)
Amiodarone (Compound) resembles Lucanthone (Compound)
Amiodarone (Compound) binds CACNA2D2 (Gene)
Amiodarone (Compound) upregulates HMGCS1 (Gene)
Amiodarone (Compound) is included by Cytochrome P450 2C9 Inhibitors (Pharmacologic Class)
Amiodarone (Compound) downregulates PRPF4 (Gene)
Amiodarone (Compound) causes Dermatitis exfoliative (Side Effect)
Amiodarone may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib